Relationship between diabetic retinopathy, microalbuminuria and overt nephropathy, and twenty-year incidence follow-up of a sample of type 1 diabetic patients

2012 ◽  
Vol 26 (6) ◽  
pp. 506-512 ◽  
Author(s):  
Pedro Romero-Aroca ◽  
Marc Baget-Bernaldiz ◽  
Javier Reyes-Torres ◽  
Juan Fernandez-Ballart ◽  
Nuria Plana-Gil ◽  
...  
2021 ◽  
pp. 112067212199057
Author(s):  
Tomás de Oliveira Loureiro ◽  
João Nobre Cardoso ◽  
Carlos Diogo Pinheiro Lima Lopes ◽  
Ana Rita Carreira ◽  
Sandra Rodrigues-Barros ◽  
...  

Background/objectives: Continuous subcutaneous insulin infusion (CSII) is a treatment for type 1 diabetes that improves metabolic control and reduces micro and macrovascular complications. The aim of this study was to compare the effect of CSII versus traditional multiple daily injections (MDI) therapy on retinal vasculature. Methods: We performed a prospective study with type 1 diabetic patients with no prior history of ocular pathology other than mild diabetic retinopathy. The patients were divided into two groups according to their therapeutic modality (CSII vs MDI). The retinal nerve fiber layers thickness and vascular densities were compared between groups in both macula and optic disc. The correlations between vascular density and clinical features were also determined. Statistical significance was defined as p < 0.05. Results: The study included 52 eyes, 28 in the insulin CSII group. The mean age was 36.66 ± 12.97 years, with no difference between groups ( p = 0.49). The mean glycated hemoglobin (HbA1c) was found to be lower in the CSII group (7.1% ± 0.7 vs 7.5% ± 0.7 p < 0.01). The parafoveal vascular density was found to be higher in the CSII group (42.5% ± 0.4 vs 37.7% ± 0.6, p < 0.01). We found an inverse correlation between HbA1c value and parafoveal vascular densities ( p < 0.01, r = −0.50). Conclusion: We found that CSII provided better metabolic control than MDI and this seemed to result in higher parafoveal vascular density. As lower vascular density is associated with an increased risk of diabetic retinopathy, these results suggest that CSII could be the safest therapeutic option to prevent retinopathy.


Ophthalmology ◽  
2009 ◽  
Vol 116 (11) ◽  
pp. 2170-2174 ◽  
Author(s):  
Jakob Grauslund ◽  
Anders Green ◽  
Anne Katrin Sjølie

2012 ◽  
Vol 38 (1) ◽  
pp. 174-179 ◽  
Author(s):  
Jonas Vejvad Nørskov Laursen ◽  
Stine Skovbo Hoffmann ◽  
Anders Green ◽  
Mads Nybo ◽  
Anne Katrin Sjølie ◽  
...  

2009 ◽  
Vol 50 (7) ◽  
pp. 3404 ◽  
Author(s):  
Hille W. van Dijk ◽  
Pauline H. B. Kok ◽  
Mona Garvin ◽  
Milan Sonka ◽  
J. Hans DeVries ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document